Pancreatic Cancer Research

ResearcherStony Brook UniversityActive in the last 2 years

Joseph Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6313-1516; OpenAlex author ID A5100650735. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
39
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 18

  1. Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2026.1675133↗
  2. Transcriptomic Profiling and Demographic Analysis of Appalachian Patients with Pancreatic Ductal Adenocarcinoma using the Purity Independent Subtyping of Tumor… Co-author DOI 10.64898/2026.09.22.26363302↗
  3. Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer. Last author DOI 10.1002/1878-0261.70062↗
  4. Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. Last author DOI 10.1245/s10434-024-16011-3↗
  5. Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.13023/jah.0601.02↗
  6. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. Co-author DOI 10.1038/s41467-023-40895-6↗
  7. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348221117031↗
  8. Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0270832↗
  9. Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Last author DOI 10.3390/cancers14133051↗
  10. Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Last author DOI 10.1038/s41416-020-0879-6↗
  11. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Last author DOI 10.1038/s41416-018-0298-0↗
  12. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Co-author DOI 10.1016/j.gie.2017.12.032↗
  13. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  14. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Last author DOI 10.1097/mpa.0000000000000379↗
  15. Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Last author DOI 10.1007/s12307-013-0130-6↗
  16. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. Last author DOI 10.1186/1479-5876-10-68↗
  17. Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0031004↗
  18. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.25763↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael J. Cavnar · 8 shared papers, 2022–2026 · strength 1.58
  2. Reema Anil Patel · 7 shared papers, 2022–2026 · strength 1.38
  3. Megan M. Harper · 5 shared papers, 2022–2025 · strength 0.90
  4. Mei Gao · 6 shared papers, 2019–2025 · strength 0.88
  5. Hannah G. McDonald · 4 shared papers, 2024–2026 · strength 0.80
  6. Anna M. Reagan · 3 shared papers, 2024–2026 · strength 0.61
  7. Chelsey Mckenna Williams · 2 shared papers, 2024–2026 · strength 0.40
  8. Emily Cassim · 2 shared papers, 2024 · strength 0.36
  9. Erin E. Burke · 2 shared papers, 2024 · strength 0.36
  10. Richard A. Moffitt · 3 shared papers, 2019–2023 · strength 0.34
  11. Deepak Vadehra · 1 shared paper, 2026 · strength 0.23
  12. Justin B. Miller · 1 shared paper, 2026 · strength 0.23
  13. Ashish Manne · 1 shared paper, 2026 · strength 0.23
  14. Carlos H.F. Chan · 1 shared paper, 2026 · strength 0.23
  15. Dae Won Kim · 1 shared paper, 2026 · strength 0.23
  16. Thomas Amburn · 1 shared paper, 2023 · strength 0.20
  17. Jeffrey L. Vacirca · 2 shared papers, 2019–2020 · strength 0.18
  18. Marcela d'Alincourt Salazar · 2 shared papers, 2019–2020 · strength 0.18
  19. Minsig Choi · 2 shared papers, 2019–2020 · strength 0.18
  20. Kenneth Reed Shroyer · 2 shared papers, 2019–2020 · strength 0.18
  21. Eileen L. Heinrich · 4 shared papers, 2012–2016 · strength 0.17
  22. Luke A. Torre-Healy · 1 shared paper, 2023 · strength 0.16
  23. Ki Oh · 1 shared paper, 2023 · strength 0.16
  24. Scott Powers · 1 shared paper, 2023 · strength 0.16
  25. Joseph F. LaComb · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.